There was minimal evidence to suggest an effect of genetically proxied LDLR mediated LDL-c levels on overall prostate cancer risk (OR = 1.04, 95% CI = 0.96 to 1.12, P = 0.385, per SD reduction in LDL-c). The gene discussed is LDLR; the disease is prostate carcinoma.